ConvaTec Group (CTEC) — Dividend Yield: 2.22%

Sector: Medical Equipment and Services | Market Cap: £4,746.38 | EPIC: CTEC

ConvaTec Group (LON: CTEC) is a global medical products and technologies company listed on the FTSE 100, with a market capitalisation of approximately £4.7 billion. The company specialises in advanced medical technologies for chronic conditions, operating across four divisions: Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Devices. ConvaTec's products improve the quality of life for millions of patients living with conditions requiring ongoing medical device support.

ConvaTec's dividend yield of approximately 2.22% provides income from a healthcare company with defensive demand characteristics. The company has a progressive dividend policy, with payments growing in line with earnings improvements. ConvaTec's products address chronic conditions that require continuous device usage, creating highly predictable recurring revenue streams that support stable dividends.

For investors seeking medical devices exposure within the FTSE 100, ConvaTec offers compelling long-term growth driven by ageing populations and increasing prevalence of chronic conditions. The global ostomy care market is growing as surgical procedures and patient populations expand, while advanced wound care benefits from rising rates of diabetes-related chronic wounds. ConvaTec's direct-to-patient relationships in ostomy and continence care create strong brand loyalty and high switching costs.

ConvaTec's innovation pipeline is focused on developing next-generation products that improve patient outcomes and comfort. The company's infusion devices division serves the insulin pump market, benefiting from the growing diabetes epidemic. ConvaTec's geographic diversification across developed and emerging markets provides balanced growth exposure. The company has undergone significant operational improvements under recent management, including margin expansion, innovation acceleration, and cultural transformation. For FTSE 100 investors seeking defensive healthcare exposure with improving operational momentum, ConvaTec represents an attractive medtech investment.